Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Ionetix Q3 2026 Results: Net Loss of $4.94M, Loss Narrows

Ionetix Corp reported a significant improvement in its liquidity position as of September 30, 2026, with cash increasing to $5.57 million from $0.28 million at the end of 2025. Total liabilities decreased substantially from $22.64 million to $6.05 million, primarily due to the settlement or conversion of short-term debt and SAFE liabilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue1.21.1
Profit before tax-4.9-6.7
Net income-4.9-6.7
EPS (diluted, $ a share)$-0.04$-0.52

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+9.0%
Operating margin-405.9%
Source

10-Q filed with the SEC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Ionetix Corp: key numbers

Shares outstanding
106.53MLatest SEC cover page
Sector
Life Sciences
Industry
In Vitro & In Vivo Diagnostic SubstancesSIC 2835

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Ionetix Corp

All →
4:02 PM ET 8-K
Stock Plan Amendment

Ionetix Stock Plan Amendment

Ionetix Corporation granted stock options to its CEO Kevin Cameron (1,025,600 shares) and CFO Phieu Phun (854,700 shares) under the 2026 Equity Incentive Plan. The options have an exercise price of $3.00 per share and follow a four-year vesting schedule. Additionally, the company adopted a new Non-Employee Director Compensation Plan governing equity awards for board members.

Term
10 years

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.